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Abstract The psychostimulant methylphenidate (MPH) is
the first choice of treatment in attention-deficit hyperactivity
disorder and is based mainly on inhibition of dopamine
transporter (DAT). Nonetheless, the complete cellular
effects of MPH are still unknown. We attempted to deter-
mine whether MPH influences neurotransmitter levels,
synaptic gene expression, and cell proliferation in a dose-
dependent manner in rat pheochromocytoma cells (PC12)
lacking DAT. PC12 were treated in a dose-dependent
manner with MPH. Gene expression level of synaptotagmin
(Syt) 1 and 4, syntaxin 1a (Stx1a), and synaptic vesicle
glycoprotein 2C (SV2C) was measured using quantitative
real-time RT-PCR. Different Neurotransmitter release was
measured using high-performance liquid chromatography
(HPLC). Differences in cell proliferation were evaluated via
BrdU incorporation. Treatment with low-dose MPH
(1–100 nM) altered intra-/extracellular neurotransmitter
levels, down-regulated all investigated genes as well as
enhanced cell proliferation significantly. These data point to
diverse effects of MPH on cell metabolism independent of
inhibiting DAT.
Keywords Methylphenidate  PC12 cells 
Synaptic Proteins  Norepinephrine Transporter 
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is the
most frequent psychiatric disorder in children and ado-
lescents, with up to 6–12% affected worldwide (Biederman
and Faraone 2005). ADHD is characterized by the con-
stitutive development of inappropriate levels of inatten-
tion, hyperactivity, and/or impulsiveness. The cause and
pathophysiology of ADHD are still unknown, but there is
immense evidence that ADHD has multiple aetiologies
(e.g. genetic, environmental, neurobiological, and neuro-
chemical) in which catecholamine dysfunction, including
afferent dopaminergic and noradrenergic neurotransmis-
sion, has an important underlying feature (Wilens 2008).
The noradrenergic system modulates higher cortical
functions, such as attention, alertness, vigilance, and
executive functions, which are impaired in a variety of
psychiatric disorders such as ADHD (Hahn, Steele et al.
2009). The norepinephrine transporter (NET), an impor-
tant component of the noradrenergic system, involves in
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the reuptake of norepinephrine (NE) into the presynaptic
terminals. A recent report implicates the involvement of
NET in ADHD (Kim, Hahn et al. 2006), in which they
identified a functional polymorphism in the human NET
gene that decreases promoter function and was signifi-
cantly associated with ADHD. Considering the neurobi-
ology of ADHD, it is reasonable to hypothesize that
medications that increase dopamine (DA) or NE avail-
ability and/or decrease their breakdown should improve
ADHD symptoms.
Stimulants are part of the standard treatment for ADHD.
Methylphenidate (MPH), a central nervous system stimu-
lant with an approximately 70-year history of use, is the
most frequently prescribed drug for the symptomatic
treatment of ADHD and has consistently shown efficacy.
However, the mechanism by which low doses of MPH
reduce the activity and increase the attention is still
unknown. Functionally, MPH is a high-affinity inhibitor of
dopamine transporter (DAT) and NET, blocking the inward
transport of DA and NE (Gatley, Pan et al. 1996; Han and
Gu 2006). A recent study showed the effect of MPH on
vesicular monoamine transporter 2 (VMAT-2) in rats after
in vivo administration. The results of the study indicated
that a single dose of MPH redistributes VMAT-2 and
associated vesicles within nerve terminals from the syn-
aptosomal membranes to the cytoplasm. In addition, MPH
administration leads to increased DA in the vesicle fraction
(Volz, Farnsworth et al. 2008). Considering these findings
and the knowledge that MPH function is not solely the
inhibition of DAT, we decided to investigate the effects of
in vitro MPH treatment in neuronal cell line devoid of DAT
expression, on neurotransmitter levels, gene expression
profile of synaptic proteins, and cell proliferation, in order
to elucidate the additional molecular mechanism of MPH.
The cell culture model chosen for this investigation was the
rat PC12 cell line, derived from rat pheochromocytoma, a
tumor arising from the chromaffin cells of the adrenal
medulla. PC12 cells are a common model for studying
neurobiochemical and neurobiological events (Jaeger
1985). These cells have been widely used as an in vitro
experimental model to study the effects of various neuro-
active compounds and contain many membrane-bound and
cytosolic neuron-associated macromolecules (Shafer and
Atchison 1991). Previously it was reported that proliferat-
ing PC12 cells highly express NET and in very low levels
express DAT, while in differentiated PC12 cells DAT
expression was detected (Kadota, Yamaai et al. 1996). We
used proliferating PC12 cells (originated form Israel, old
generation ATCC) in which we could detect high expres-
sion of NET but no DAT expression at all whatsoever (see
Suppl. Figure S1 and S2), which makes this model an ideal
model to study MPH effects not associated with DAT
inhibition.
Materials and methods
Cell culture
PC12 cells used in this study were generous gift from the
laboratory of Dr. Silvia Mandel, Technion Faculty of
Medicine, Haifa, Israel (old generation originating from
ATCC) and grown in buffered Dulbecco‘s modified Eagle
medium (DMEM) (Pan Biotech GmbH, Aidenbach,
Germany) supplemented with 10% fetal bovine serum, 5%
horse serum, and 0.3% gentamycin (50 mg/ml) (Invitrogen,
Karlsruhe, Germany) in a humidified incubator (5% CO2)
at 37C.
MPH treatment
For high-performance liquid chromatography (HPLC),
quantitative real-time polymerase chain reaction (QRT-
PCR), and BrdU incorporation experiments, PC12 cells
were treated with varying concentrations of MPH (Sigma–
Aldrich, Schnellendorf, Germany) (1, 10, 100 nM, 1, 10,
100 lM), or purified water as a control, by adding it to the
culture medium.
For BrdU incorporation analysis, the MPH incubation
was stopped after 24 h. For QRT-PCR and HPLC, the
reaction was stopped after 48 h. MPH was protected from
light for all treatments, and the dilutions were always
freshly prepared. The cells were incubated with MPH
under dark conditions in order to reduce MPH degradation.
Handling MPH in the dark delays the drug’s degradation
reaction (Suppl. Figure S3).
Catecholamine determination via HPLC
PC12 cells were plated at a density of 4 9 105 cells/mL
into a 24-well plate (Sarstedt, Nuembrecht, germany) and
treated with MPH as described above. Reverse-phase
HPLC was used to measure the intracellular and extracel-
lular concentrations of DA, its metabolites 3,4-dihydroxy-
phenylacetic acid (DOPAC) and homovanillic acid (HVA);
NE, its metabolite 3-methoxy-4-hydroxy-phenylglycol
(MHPG); and serotonin (5-HT) and its metabolite
5-hydroxyindole acetic acid (5-HIAA). Cells were soni-
cated in ice-cold 90% (v/v) 0.1 mM Na2PO4 (pH 4.0) and
10% (v/v) methanol containing 0.1 mM EDTA (Sigma,
Munich, Germany), 0.65 mM octanesulfonic acid, and 0.5
mM triethylamine. Homogenates were centrifuged at
19,000g for 20 min at 4C and the supernatants were used
for the measurements. For the analysis of neurotransmitters
and metabolites, the supernatants from cell homogenates or
medium from the cell culture suspensions were measured
using HPLC as described by Riederer and Reynolds
(1981). The concentrations of DA, DOPAC, HVA, NE,
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MHPG, 5-HT, and 5-HIAA in the cell culture medium
were measured before the experiment and subtracted from
the concentration measured at the end of the experiment to
obtain the amount of neurotransmitter released. Probes
were quantified using an external standard that contained
all detected neurotransmitters and metabolites at different
concentrations (80 ng/mL, 40 ng/mL, and 20 ng/mL).
Immunocytochemistry
PC12 cells were plated at a density of 1.5 9 105 cells/mL in
poly-D-lysine/laminin-coated culture slides (BD Biosciences,
Heidelberg, Germany) and differentiated with 50 ng/mL
human NGF-b (Sigma, Munich, Germany) for 7 days (this
procedure was conducted only for the immunocytochemical
analysis). After incubation, the cells were washed in phos-
phate-buffered saline (PBS) and fixed with ice-cold acetone/
methanol (1:1) for 10 min. After three PBS washes, the cells
were incubated with a blocking solution containing 5% goat
serum and 0.3% Triton X-100 in PBS for 2 h at room tem-
perature to block non-specific binding. The cells were then
incubated overnight in antiserum diluted in blocking solution
1:50 for synaptotagmin 1 (syt1) (Abcam, Cambridge, MA,
USA), synaptotagmin 4 (syt4) (Santa Cruz Biotechnology,
Heidelberg, Germany), and syntaxin 1A (stx1a) (Lifespan
Biosciences, Seattle, WA) and 1:100 for synaptophysin (syp)
(Sigma). Cells were subsequently incubated with cyanine 2-
and 3 (Cy3 and Cy2)-labeled secondary antibodies diluted
(1:200) in blocking solution for 2 h in the dark at room
temperature to visualize the bound primary antibody. After
washing, cells were mounted with Vectashield (Vector Lab-
oratories, Burlingame, CA, USA). Immunofluorescence was
observed using a Leica TCS SP2 confocal microscope.
RNA extraction and QRT-PCR
PC12 cells were plated at a density of 4 9 105 cells/mL into
a 24-well plate (Sarstedt, Nuembrecht, germany) and treated
with MPH as described above. Total RNA was extracted
from PC12 cells using the RNeasy Plus MiniKit (Qiagen,
Hilden, Germany) according to the manufacturer’s instruc-
tions. Total RNA (500 ng) was reverse transcribed using the
iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Munich,
Germany). QRT-PCR was performed using an iCycler iQTM
Real Time PCR Detection System (Bio-Rad) and the SYBR-
Green detection method. The QRT-PCR reaction was
optimized according to the manufacturer’s instructions.
QuantiTech Primer assays for syt1 (catalog no. QT01573
019), syt4 (QT00195664), stx1a (QT01083229), NET
(QT00184604), b-actin (Actb; QT00193473), aminolevuli-
nic acid synthase 1 (Alas1; QT00436310), and ribosomal
protein L13A (Rpl13a; QT00425873) were purchased from
Qiagen. Actb, Alas1, and Rpl13a were used for normaliza-
tion according to GeNorm (Vandesompele et al. 2002).
The amplified transcripts were quantified using the
comparative threshold cycle (Ct) analyzed using the BioRad
iCycler iQ program.
BrdU incorporation
PC12 cells were plated at a density of 1 9 105 cells/mL in
poly-D-lysine/laminin-coated culture slides (BD Biosciences)
and incubated at 37C overnight in a humidified atmosphere
of 5% CO2. The next day, settled cells were treated with
different doses of MPH and incubated for 24 h under the
same conditions.
To identify the proliferating cells and cells in S-phase of
the cell cycle under proliferating conditions, cells were
exposed to 10 lM BrdU (Roche) for 4 h at 37C for
incorporation into newly synthesized DNA. Cells were
then fixed with 4% paraformaldehyde for 20 min. Three
PBS washes were performed prior to DNA denaturation
with 2 M HCl for 45 min at room temperature. Neutral-
ization was carried out by incubating cells in 0.15 M
sodium borate buffer for 10 min at room temperature. The
cells were then washed three times with PBS. The cells
were incubated with blocking solution for 2.5 h at room
temperature to block non-specific binding. The cells were
then incubated with primary mouse anti-BrdU (1:100)
overnight at 4C. Antibody detection was performed as
described in the ‘‘Immunocytochemistry’’ part. Sixteen
independent experiments were conducted, and BrdU
incorporation was done in duplicate with four evaluated
pictures for each dose (n = 16). The BrdU-positive cells
were calculated as percentage to all stained cells.
Statistical analysis
Statistical analyses of the HPLC, QRT-PCR, and prolifer-
ation data were performed using StatView for Windows
(SAS Institute Inc., version 5). Statistical tests included
analysis of variance (ANOVA) with post hoc Scheffe Test.
Significance was set as P \ 0.05. For a better comparison
of the data, we normalized the results and converted the
data into percentages. The control group was set as 100%.
Results
Using Western blot and real-time PCR for the detection of
DAT and NET in PC12, we could show that the PC12
obtained from Israel presented no DAT expression but a
high NET expression (Suppl. Figure S1 and S2).
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Neurotransmitter alteration in MPH-treated PC12 cells
Alteration of NE and MHPG levels
The intracellular NE concentration was 3–19 ng/mL.
Higher NE concentrations were measured in the cell
medium (extracellular) (50–120 ng/mL). The extracellular
MHPG concentration was below the level of detection
(\2.2 ng/mL).
The intracellular NE concentration was significantly
reduced by MPH treatment compared to control at doses of
10 nM–100 lM (-30% for 10 nM; -80% for 100 nM, 1,
and 10 lM; and -88% for 100 lM; P \ 0.001; Fig. 1a). On
the other hand, intracellular MHPG levels increased at low
doses of MPH (1–100 nM; Fig. 1a). The turnover rate of NE
seems to increase as a consequence of MPH treatment
(Suppl. Table S1). The extracellular concentration of NE
significantly increased at MPH doses of 1–100 nM
(?70–80% compared to control, P \ 0.01). Since the
extracellular MHPG levels were below the limits of HPLC
sensitivity, no alterations could be observed in the extra-
cellular samples.
Alterations of DA, DOPAC, and HVA levels
The intracellular DA concentration was 30–120 ng/mL,
whereas the extracellular concentration was 9–160 ng/mL.
Intracellular DOPAC concentrations were 3–5 ng/mL, and
the extracellular concentration was 26–120 ng/mL. The
intracellular HVA concentration was below the level of
detection, whereas the extracellular concentration was
400–1,300 ng/mL.
The intracellular DA concentration increased signifi-
cantly with MPH doses of 1–100 nM (1 nM ?35%, 10 nM
?37%, 100 nM ?58% compared to control; P \ 0.02;
Fig. 1b) and decreased after treatment with 10 lM or
100 lM MPH, but the decrease was only significant for
100 lM (-52% compared to control, P \ 0.0001; Fig. 1B).
No significant effect on intracellular DOPAC and HVA
levels was observed after MPH treatment (Fig. 1b).
Similarly, the turnover of DA into DOPAC was not signif-
icantly altered as a consequence of MPH treatment (Suppl.
Table S1).
The extracellular concentration of DA was significantly
decreased after treatment with 1–100 nM MPH (-90 to -95%
compared to control, P \0.0001), whereas no alteration in the
extracellular DA concentration was observed at high doses
(Fig. 1b). A significant decrease in the extracellular DOPAC
concentration (-70 to -75% compared to control,
P \0.0005) was observed only at high MPH doses
(1–100 lM). After treatment with low doses of MPH, the
extracellular HVA concentration significantly increased (1 nM
?180%, P\ 0.0001; 10 nM ?187%, P\ 0.0001; 100 nM
?220%, P \ 0.0001), whereas treatment with high doses of
MPH led to no relevant effect on the extracellular HVA con-
centration (Fig. 1b). An increased turnover of DA to HVA was
observed at the lower doses of MPH (1–100 nM), whereas
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Fig. 1 Dose-dependent alteration of neurotransmitter levels in MPH-
treated PC12 cells represented as a percent of the control
(MPH = 0 nM). a Norepinephrine (NE) and its metabolite 3-meth-
oxy-4-hydroxyphenylglycol (MHPG), b dopamine (DA) and its
metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic
acid (HVA), c serotonin (5-HT) and its metabolite 5-hydroxyindole
acetic acid (5-HIAA) were measured in pellets (P = intracellular) and
the medium (M = extracellular). Independent experiments were
conducted eight times, and HPLC measurements were done in
duplicate (n = 8). **P \ 0.0001 vs. MPH = 0 nM; *P \ 0.05 vs.
MPH = 0 nM using one-way ANOVA with post hoc Scheffe test.
Error bars represent standard error in percent
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decreased turnover to DOPAC was observed at higher doses
(Suppl. Table S1).
Alteration of 5-HT and 5-HIAA levels
The intracellular 5-HT concentration was 3–5 ng/mL, but
intracellular 5-HIAA was below the level of detection. The
intracellular concentration of 5-HT and 5-HIAA was not
significantly altered as a consequence of treatment with
MPH at any dose (Fig. 1c).
The extracellular 5-HT concentration was 40–115 ng/mL,
and the extracellular 5-HIAA concentration was 14–107
ng/mL. The 5-HT concentration was significantly decreased
after treatment with 1–100 lM MPH (1 lM, -65%; 10 lM,
-60%; 100 lM, -40% compared to control, P \ 0.009), and
the 5-HIAA concentration was significantly increased after
treatment with lower doses of MPH (1 nM ?430%; 10 nM
?440%; 100 nM ?380% compared to control, P \ 0.0001).
Extracellular 5-HT turnover to 5-HIAA was increased,
especially at lower MPH doses (1–100 nM; Suppl. Table S1).
Localization of syt1, syt4, and stx1a in PC12 cells
The synaptic proteins syt1, syt4, and stx1a were detected in
untreated PC12 cells via immunocytochemistry. Figure 2
shows the distribution and localization of the proteins with the
neuronal vesicle protein syp (Fig. 2a, d, g) within the cells.
Syt1 staining was located mainly in the soma (Fig. 2b).
Similarly, syt4 expression was found in the cell body and
punctuated in neurite-like processes (Fig. 2e). A high density
of accumulated protein was perinuclear, possibly in the Golgi
apparatus (Fig. 2f, arrow). The distribution pattern of syp and
syt4 mostly correlated with one another. Stx1a was spread in
most areas of the PC12 cells (Fig. 2h). Stx1a showed a similar
distribution pattern as syp with a high level of coincidence
(Fig. 2i). The cell’s nucleus was unstained in all cases.
overlayed
overlayed
overlayed
syt1
syt4
stx1a
syp
syp
syp
Fig. 2 Colocalization of synaptic proteins with synaptophysin (syp)
on poly-D-lysine/laminin in PC12 cells. The immunolocalization of
syp (a, d, g) revealed by a Cy2-coupled secondary antibody (green)
was compared with syt1 (b), syt4 (e), and stx1a (h) immunostaining
revealed by a Cy3-coupled secondary antibody (red) and superim-
posed (yellow; c, f, i). The arrow indicates strong perinuclear syt4
staining. Scale bar 100 lm
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Gene expression profiles for synaptic proteins
in MPH-treated PC12 cells
The influence of dose-dependent treatment with MPH on
the expression of syt1, syt4, stx1a, and NET in the rat PC12
cell line was tested using QRT-PCR (Fig. 3). The expres-
sion of mRNA for all investigated genes was significantly
reduced after treatment with 1 nM MPH. Syt1 was down-
regulated 43% (P \ 0.0001) compared to the control
group. Additionally, the expression of syt4 (-20%,
P = 0.04), stx1a (-15%, P = 0.045), and NET (-27%,
P = 0.0014) was down-regulated compared to the control.
Higher doses of MPH did not show significant changes
after ANOVA one-way post hoc Scheffe, but a significant
down-regulation of NET after treatment with 10 (-20%),
100 nM (-26%), and with 10 lM (-15%) was observed
using a less conservative test (the student’s t-test).
Low doses of MPH enhance PC12 cell proliferation
Because cell proliferation is associated with de novo DNA
synthesis, we stained MPH-treated and untreated cells with
BrdU to visualize its incorporation into DNA. A signifi-
cantly larger population of PC12 cells displayed active
DNA synthesis when treated with lower doses of MPH
(1, 10, 100 nM) compared to control (?10–20% enhanced
proliferation versus control, P \ 0.05; Fig. 4). Higher
doses of MPH (1, 10, 100 lM) had no effect on cell
proliferation.
Discussion
In this work, we presented the effects of low-dose MPH
treatments after a short time at the level of extracellular and
intracellular neurotransmitters and their metabolites, as well
as its dose-dependent transcriptional effects on the expres-
sion of synaptic protein genes, excluding its inhibitory
effects on the DAT (Suppl. Figure S1 and S2). A recent study
used low doses of MPH (lowest dose *130 nM) to treat
human neuroblastoma cell line to investigate the effect on
cell survival (Schmidt et al. 2009). However, to the best of
our knowledge, the present study is the first to deal with the
impact of even lower doses of MPH. We showed that very
low doses of MPH (1–100 nM) affect intra and extracellular
neurotransmitter levels. The NE concentration was signifi-
cantly higher (70–80%) in the medium of treated PC12 cells
compared to untreated cells, whereas the intracellular levels
of NE were significantly lower after treatment with nano-
molar concentrations of MPH. This outcome is generally
consistent with the literature describing the interactions of
this psychostimulant with biogenic amine transporter sys-
tems (Berridge, Devilbiss et al. 2006). MPH has been shown
to inhibit NE uptake (Ferris, Tang et al. 1972; Wall, Gu et al.
1995) and bind to DAT and NET with high affinity, which
leads to a higher extracellular monoaminergic level (Gatley,
Pan et al. 1996; Volkow et al. 2002). Here, we report a novel
finding; the intracellular DA concentration was significantly
higher, whereas lower extracellular DA levels were detected
after treatment with low doses of MPH. These results con-
firm with our additional finding that syt1 (one of our
investigated synaptic protein) was also down-regulated after
nanomolar treatment with MPH. Roden et al. (Roden, Papke
et al. 2007) could show that after a stable RNA interference
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Fig. 3 Methylphenidate (MPH) dose-dependent gene expression
profiles in PC12 cells represented as the percent of control cells
(MPH = 0 nM). Gene expression was normalized to three house-
keeping genes using the GeNorm method. Independent experiments
were conducted twelve times, and QRT-PCR measurements were
done in triplicate (n = 12). Syntaxin 1a stx1a; synaptotagmin 1 syt1;
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MPH = 0 nM using one-way ANOVA with post hoc Scheffe test.
Error bars represent standard error in percent
80
90
100
110
120
130
0nM 1nM 10nM 100nM 1µM 10µM 100µMBr
dU
 in
co
rp
or
at
io
n 
(%
 of
 co
nt
ro
l)
Methylphenidate
**
**
*
Fig. 4 Methylphenidate (MPH) dose-dependent effect on PC12 cell
proliferation represented as the percent of control cells
(MPH = 0 nM). Independent experiments were conducted sixteen
times, and BrdU incorporation was done in duplicate with four
evaluated pictures for each dose (n = 16). The BrdU-positive cells
were percental calculated to all stained cells **P \ 0.01, *P \ 0.05
vs. MPH = 0 nM using one-way ANOVA with post hoc Scheffe test.
Error bars represent standard error in percent
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of syt1 in PC12 cells, the DA release was 50% lower. They
also found that NE release was lower, but because MPH is a
potential NET blocker it seems that this effect is abrogated in
our experiment with the PC12 lacking DAT (Suppl. Figure
S1 and S2). MPH activation of the synthesizing enzyme,
tyrosine hydroxyls, might also be one of the reasons to the
increased DA levels, but this must be investigated for con-
firmation. Another potential reason for the higher intracel-
lular DA level could be our findings regarding cell
proliferation, although this must be interpreted cautiously
since we would have expected than that all neurotransmitters
would have increased at this dose treatment. Cell prolifer-
ation was enhanced significantly by 1–100 nM of MPH,
whereas higher doses (1–100 lM) caused no alteration. In
contrast to (Lagace, Yee et al. 2006), who demonstrated an
inhibition of neurogenesis in the juvenile rat brain after
MPH administration, we could show higher proliferation
rate in PC12 cells after low doses of MPH. Our present study
as well as the other cell culture studies (Ludolph, Schaz et al.
2006) revealed mainly increased cell survival and prolifer-
ation after MPH treatment. However, one has to be cautious
about constructing a link between in vitro cell culture results
and in vivo mechanisms. In addition, we demonstrated that
the change in extracellular DA metabolites DOPAC and
HVA correlated with the breakdown of DA. After nano-
molar MPH treatment, the extracellular DOPAC and HVA
levels were higher compared to the intracellular level. The
degradation of DA seems to be enhanced after MPH treat-
ment; which might be through the activation of monoamine
oxidase-B or catechol-O-methyltransferase activities via
MPH. But such hypothesis should be further investigated.
The result obtained for the 5-HT metabolite 5-HIAA is
an additional evidence for this potential hypothesis. In this
case, we obtained also extracellularly the most significant
results at nanomolar doses for 5-HIAA (5-HT metabolite).
Interestingly, as soon as we raised the MPH doses to the
micromolar range, the extracellular DA level was higher
than the intracellular level, which is in accordance with
previous reports showing that MPH increases the extra-
cellular level of DA (Kuczenski and Segal 1997; Easton,
Steward et al. 2007; Volz, Farnsworth et al. 2008).
We used much lower doses of MPH to demonstrate the
potency of MPH at lower doses than what was expected
until now. Using a cell line model, we must take into
account that doses used in vitro should be conferred to an
in vivo model; therefore, an adaptation of the drug doses
from the micromolar range to the nanomolar range has to
be assumed. We showed that low doses of MPH not only
alter neurotransmitter release, but also influence synaptic
gene expression. We investigated the expression of NET
and synaptic protein genes, including syt1, syt4, and stx1a,
which is a part of the soluble N-ethylmaleimide-sensitive
factor attachment receptor (SNARE) core complex.
SNARE proteins assemble into a very stable a-helical
complex between two membranes. The formation of the
SNARE complex brings two membranes closer and thus
leads to membrane fusion. A previous study (Sung and
Blakely 2007) demonstrated a direct interaction between
NET and stx1a, a protein involved in vesicle trafficking
and docking. Importantly, the NET/stx1a interaction
appears to be not irrevocable, but rather can be modulated
rapidly by extracellular stimuli such as a psychostimulant.
Stx1a regulates NET through two mechanisms, one
involving the delivery of NET to the plasma membrane and
a second involving the inactivation of its catalytic function.
How these mechanisms are linked to neuronal activation or
second messenger responses remains to be elucidated. Our
results show that stx1a mRNA decreases after all MPH
doses, but a significant effect was observed only with 1 nM
MPH. Interestingly, all investigated synaptic proteins and
NET are down-regulated at this low concentration. The
significant down-regulation of synaptic proteins by 1 nM
MPH shows a strong link to the extracellular DA level. We
measured a much lower DA level in the medium after
treatment with 1 nM MPH compared to untreated cells
(Fig. 1b). Synaptic protein expression can be regulated by
the dopamine receptor pathway. DA can activate extra-
cellular signal-regulated kinase (ERK) signaling by stim-
ulating both the D1- and the D2-family receptors. Zachor
and colleagues demonstrated for the first time that wild-
type PC12 cells express D1 and D2 receptor proteins
(Zachor, Moore et al. 2000). Activated ERK induces cAMP
response element-binding protein (CREB) phosphorylation
and c-fos expression, which further regulate target gene
expression, including synaptic proteins. Changes in the
expression of these genes may contribute to different
aspects of long-term neuro-adaptation (Zhang and Xu
2006). The consequence of low levels of DA is a decreased
expression of synaptic proteins. Comparing the gene
expression profiles of syt1 and NET after treatment with
MPH, they have almost the same progression, which might
indicate a common mechanism of action. This theory must
be further investigated.
Summarizing our results, we showed that much lower
MPH doses than expected are biologically active and lead
to an alteration of neurotransmitter release, neurotrans-
mitter metabolism, cell proliferation, and the expression of
certain genes. Additional investigations into intermediate
nanomolar doses of MPH are necessary for further
confirmation.
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